LEGIC Partners with PassiveBolt to Revolutionize the World of Decentralized Identity at the Chip Level
The groundbreaking collaboration aims to mainstream Self-Sovereign Identity (SSI) across industries by integrating it at…
News
EduSynch and RV Technical Institute Partner to Streamline Online Certification with Remote Proctoring Technology
NEW YORK–(BUSINESS WIRE)–#EdTech—EduSynch, a global pioneer in online assessment and exam security solutions, is…
SLM Holdings Announces Strategic Partnerships with Chicago Investors to Elevate Its Intelligent Banking System
Chicago, Illinois–(Newsfile Corp. – October 9, 2023) – SLM Holdings, a leading fintech startup, is…
General Micro Systems (GMS) Demonstrates X9 Spider Manpack Mobile, Rugged Tablet, X9 Artificial Intelligence Computer and Mission Computer at AUSA 2023
Live demonstrations of revolutionary wearable X9 Spider Manpack computer and ruggedized tablet, optimized for dismounted…
HR Tech Attendees to Get Customized Skills Ontology Action Plans and Skills Datasets from Phenom
On-site Assessments will Empower Talent Management Teams with Customized Plans to Quickly Adopt AI-Powered Skills…
The Pershing Square Foundation’s MIND (Maximizing Innovation in Neuroscience Discovery) Prize Is Now Accepting Applications for its 2024 Prize
NEW YORK–(BUSINESS WIRE)–The Pershing Square Foundation has announced the opening of applications for the 2024…
Kingston FURY DDR4 UDIMMs Get a New Look
Kingston FURY Renegade DDR4 RGB & Non-RGB Kingston FURY Beast DDR4 RGB Optimized for Intel®…
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
ROCKVILLE, Md., Oct. 09, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
ROCKVILLE, Md., Oct. 09, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a…
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a…
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data…
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data…
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data SOUTH…
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data SOUTH…
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that…
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that…
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of…
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of…
MDxHealth Reports Preliminary Q3-2023 Revenues
NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 OCTOBER 2023, 4PM ET / 22:00 CET …